Ascentage Pharma files to sell American Depositary Shares, no amount given

ASCENTAGE PHARMA Announces Grant of 440,700 Restricted Share Units Under 2021 Plan

Ascentage Pharma announces clinical updates from EHA2026

ASCENTAGE PHARMA GROUP (ASX: 06855) Discloses Multiple Clinical Advances at 2026 European Hematology Association Congress

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

ASCENTAGE PHARMA Group Acquires 110,000 Shares for 2022 Restricted Stock Unit Plan

ASCENTAGE PHARMA GROUP Acquires 190,000 Shares Under 2022 Restricted Share Unit Plan

Ascentage Pharma initiated with a Buy at B. Riley

B. Riley Initiates Ascentage Pharma Group International at Buy With $45 Price Target

Piper Sandler Keeps Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)

GTHT Initiates Coverage on ASCENTAGE PHARMA GROUP with 'Add' Rating and HK$59.09 Target

Ascentage Pharma presents data on olverembatinib

Ascentage Pharma presents first dataset of alrizomadlin

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Ascendage Pharma-B Reaches Milestone of Removing 'B' Label and Showcases Major Achievements at ASCO, Unleashing Global Innovation Value

ASCENTAGE PHARMA GROUP-B Executes Share Purchase for Incentive Plan

ASCENTAGE PHARMA GROUP-B Purchases 100,000 Shares Under 2022 Restricted Stock Unit Plan

ASCENTAGE-B to Drop "B" Designation from Company Name in 2026